CLRB Stock Overview
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Cellectar Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.90 |
52 Week High | US$4.45 |
52 Week Low | US$1.56 |
Beta | 0.99 |
11 Month Change | -23.39% |
3 Month Change | -41.36% |
1 Year Change | 9.83% |
33 Year Change | -78.77% |
5 Year Change | -91.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
Aug 08Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Feb 12Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Aug 05Cellectar announces reverse stock split
Jul 21We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
May 10Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
Jan 20Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Oct 05Cellectar shares fall after mid-stage CLR 131 trial data fails to impress
Jun 04We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
May 20Cellectar Biosciences EPS beats by $0.03
May 10Cellectar gets notification of formal grant from Australian and Mexican patent authorities
Apr 27Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer
Jan 12Cellectar Bio readies stock offering
Dec 23We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Nov 30Cellectar Biosciences EPS beats by $0.05
Nov 09Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors
Nov 05Shareholder Returns
CLRB | US Biotechs | US Market | |
---|---|---|---|
7D | -11.6% | -4.9% | -5.7% |
1Y | 9.8% | 11.5% | 14.1% |
Return vs Industry: CLRB underperformed the US Biotechs industry which returned 13.1% over the past year.
Return vs Market: CLRB underperformed the US Market which returned 14.1% over the past year.
Price Volatility
CLRB volatility | |
---|---|
CLRB Average Weekly Movement | 13.2% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CLRB's share price has been volatile over the past 3 months.
Volatility Over Time: CLRB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 20 | Jim Caruso | www.cellectar.com |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
Cellectar Biosciences, Inc. Fundamentals Summary
CLRB fundamental statistics | |
---|---|
Market cap | US$69.91m |
Earnings (TTM) | -US$50.98m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs CLRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLRB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$50.98m |
Earnings | -US$50.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.42 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CLRB perform over the long term?
See historical performance and comparison